Literature DB >> 28228560

Expression of IL-22 in the Skin Causes Th2-Biased Immunity, Epidermal Barrier Dysfunction, and Pruritus via Stimulating Epithelial Th2 Cytokines and the GRP Pathway.

Hongfei Lou1,2, Jingning Lu1, Eun Byul Choi1, Min Hee Oh1, Mingeum Jeong1, Sara Barmettler1, Zhou Zhu1, Tao Zheng3.   

Abstract

Increased expression of Th22 cytokine IL-22 is a characteristic finding in atopic dermatitis (AD). However, the specific role of IL-22 in the pathogenesis of AD in vivo has yet to be elucidated. Consistent with observations in human AD, IL-22 was significantly increased in the AD skin of mice after epicutaneous sensitization to house dust mite allergen. Utilizing a skin-specific inducible transgenic system, we show in the present study that expression of IL-22 in the skin of mice caused an AD-like phenotype characterized by chronic pruritic dermatitis associated with Th2-biased local and systemic immune responses, downregulation of epidermal differentiation complex genes, and enhanced dermatitis upon epicutaneous allergen exposure. IL-22 potently induced the expression of gastrin-releasing peptide (GRP), a neuropeptide pruritogen, in dermal immune cells and sensory afferents and in their skin-innervating sensory neurons. IL-22 also differentially upregulated the expression of GRP receptor (GRPR) on keratinocytes of AD skin. The number of GRP+ cells in the skin correlated with the AD severity and the intensity of pruritus. IL-22 directly upregulated the expression of epithelial-derived type 2 cytokines (thymic stromal lymphopoietin and IL-33) and GRP in primary keratinocytes. Furthermore, GRP not only strongly induced thymic stromal lymphopoietin but it also increased the expression of IL-33 and GRPR synergistically with IL-22. Importantly, we found that the expression of GRP was strikingly increased in the skin of patients with AD. These results indicate that IL-22 plays important pathogenic roles in the initiation and development of AD, in part through inducing keratinocyte production of type 2 cytokines and activation of the GRP/GRPR pathway.
Copyright © 2017 by The American Association of Immunologists, Inc.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28228560      PMCID: PMC5360537          DOI: 10.4049/jimmunol.1600126

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  85 in total

Review 1.  Bacterial infections and atopic dermatitis.

Authors:  K Breuer; A Kapp; T Werfel
Journal:  Allergy       Date:  2001-11       Impact factor: 13.146

2.  House dust mite (HDM) antigen in naturally occurring lesions of atopic dermatitis (AD): the relationship between HDM antigen in the skin and HDM antigen-specific IgE antibody.

Authors:  K Maeda; K Yamamoto; Y Tanaka; S Anan; H Yoshida
Journal:  J Dermatol Sci       Date:  1992-03       Impact factor: 4.563

Review 3.  Barrier Epithelial Cells and the Control of Type 2 Immunity.

Authors:  Hamida Hammad; Bart N Lambrecht
Journal:  Immunity       Date:  2015-07-21       Impact factor: 31.745

4.  Interleukin-1beta induces substance P release from primary afferent neurons through the cyclooxygenase-2 system.

Authors:  A Inoue; K Ikoma; N Morioka; K Kumagai; T Hashimoto; I Hide; Y Nakata
Journal:  J Neurochem       Date:  1999-11       Impact factor: 5.372

Review 5.  Functions of T cells in asthma: more than just T(H)2 cells.

Authors:  Clare M Lloyd; Edith M Hessel
Journal:  Nat Rev Immunol       Date:  2010-11-09       Impact factor: 53.106

6.  Global variations in prevalence of eczema symptoms in children from ISAAC Phase Three.

Authors:  Joseph A Odhiambo; Hywel C Williams; Tadd O Clayton; Colin F Robertson; M Innes Asher
Journal:  J Allergy Clin Immunol       Date:  2009-12       Impact factor: 10.793

7.  Human epithelial cells trigger dendritic cell mediated allergic inflammation by producing TSLP.

Authors:  Vassili Soumelis; Pedro A Reche; Holger Kanzler; Wei Yuan; Gina Edward; Bernhart Homey; Michel Gilliet; Steve Ho; Svetlana Antonenko; Annti Lauerma; Kathleen Smith; Daniel Gorman; Sandra Zurawski; Jon Abrams; Satish Menon; Terri McClanahan; Rene de Waal-Malefyt Rd; Fernando Bazan; Robert A Kastelein; Yong-Jun Liu
Journal:  Nat Immunol       Date:  2002-06-10       Impact factor: 25.606

Review 8.  Skin barrier and immune dysregulation in atopic dermatitis: an evolving story with important clinical implications.

Authors:  Tali Czarnowicki; James G Krueger; Emma Guttman-Yassky
Journal:  J Allergy Clin Immunol Pract       Date:  2014-04-25

9.  TRPA1-dependent pruritus in IL-13-induced chronic atopic dermatitis.

Authors:  Min-Hee Oh; Sun Young Oh; Jingning Lu; Hongfei Lou; Allen C Myers; Zhou Zhu; Tao Zheng
Journal:  J Immunol       Date:  2013-10-18       Impact factor: 5.422

Review 10.  Deciphering the complexities of atopic dermatitis: shifting paradigms in treatment approaches.

Authors:  Donald Y M Leung; Emma Guttman-Yassky
Journal:  J Allergy Clin Immunol       Date:  2014-10       Impact factor: 10.793

View more
  34 in total

1.  Ets1 suppresses atopic dermatitis by suppressing pathogenic T cell responses.

Authors:  Choong-Gu Lee; Ho-Keun Kwon; Hyeji Kang; Young Kim; Jong Hee Nam; Young Ho Won; Sunhee Park; Taemook Kim; Keunsoo Kang; Dipayan Rudra; Chang-Duk Jun; Zee Yong Park; Sin-Hyeog Im
Journal:  JCI Insight       Date:  2019-03-07

Review 2.  Spinal Mechanisms of Itch Transmission.

Authors:  Devin M Barry; Admire Munanairi; Zhou-Feng Chen
Journal:  Neurosci Bull       Date:  2017-04-01       Impact factor: 5.203

3.  Evolution of pathologic T-cell subsets in patients with atopic dermatitis from infancy to adulthood.

Authors:  Tali Czarnowicki; Helen He; Talia Canter; Joseph Han; Rachel Lefferdink; Taylor Erickson; Stephanie Rangel; Naoya Kameyama; Hyun Je Kim; Ana B Pavel; Yeriel Estrada; James G Krueger; Amy S Paller; Emma Guttman-Yassky
Journal:  J Allergy Clin Immunol       Date:  2019-10-15       Impact factor: 10.793

Review 4.  Severe Atopic Dermatitis in Children.

Authors:  Evie Huang; Peck Y Ong
Journal:  Curr Allergy Asthma Rep       Date:  2018-05-10       Impact factor: 4.806

5.  Efficacy and safety of fezakinumab (an IL-22 monoclonal antibody) in adults with moderate-to-severe atopic dermatitis inadequately controlled by conventional treatments: A randomized, double-blind, phase 2a trial.

Authors:  Emma Guttman-Yassky; Patrick M Brunner; Avidan U Neumann; Saakshi Khattri; Ana B Pavel; Kunal Malik; Giselle K Singer; Danielle Baum; Patricia Gilleaudeau; Mary Sullivan-Whalen; Sharon Rose; Shelbi Jim On; Xuan Li; Judilyn Fuentes-Duculan; Yeriel Estrada; Sandra Garcet; Claudia Traidl-Hoffmann; James G Krueger; Mark G Lebwohl
Journal:  J Am Acad Dermatol       Date:  2018-01-17       Impact factor: 11.527

6.  New and Emerging Therapies for Pediatric Atopic Dermatitis.

Authors:  Henry L Nguyen; Katelyn R Anderson; Megha M Tollefson
Journal:  Paediatr Drugs       Date:  2019-08       Impact factor: 3.930

Review 7.  Keratinocytes: innate immune cells in atopic dermatitis.

Authors:  P Chieosilapatham; C Kiatsurayanon; Y Umehara; J V Trujillo-Paez; G Peng; H Yue; L T H Nguyen; F Niyonsaba
Journal:  Clin Exp Immunol       Date:  2021-02-15       Impact factor: 5.732

8.  Skin tape sampling technique identifies proinflammatory cytokines in atopic dermatitis skin.

Authors:  Taras Lyubchenko; Hannah K Collins; Elena Goleva; Donald Y M Leung
Journal:  Ann Allergy Asthma Immunol       Date:  2020-09-05       Impact factor: 6.347

Review 9.  Immunological Aspects of Skin Aging in Atopic Dermatitis.

Authors:  Georgeta St Bocheva; Radomir M Slominski; Andrzej T Slominski
Journal:  Int J Mol Sci       Date:  2021-05-27       Impact factor: 5.923

Review 10.  The Implications of Pruritogens in the Pathogenesis of Atopic Dermatitis.

Authors:  Lai-San Wong; Yu-Ta Yen; Chih-Hung Lee
Journal:  Int J Mol Sci       Date:  2021-07-05       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.